StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3020% above fair value
$554.73−4.37 (-0.78%)

Close on Nov 20, 2026Market cap $23.79BP/E 19.8Yield –

United Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

United Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $1.09B, up 2.1% year over year. For fiscal 2025 it was $1.04B, down 3.7% from the year before. Over ten years it grew 12.1% a year on average. The highest annual figure on record is $1.08B in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.04B-3.7%
FY2024Dec 31, 2024$1.08B+44.5%
FY2023Dec 31, 2023$747.60M+12.6%
FY2022Dec 31, 2022$663.70M+39.0%
FY2021Dec 31, 2021$477.40M-31.4%
FY2020Dec 31, 2020$696.40M–
FY2019Dec 31, 2019-$290.30M-148.9%
FY2018Dec 31, 2018$594.00M+53.1%
FY2017Dec 31, 2017$387.90M-35.9%
FY2016Dec 31, 2016$605.60M+81.9%
FY2015Dec 31, 2015$333.00M+8.2%
FY2014Dec 31, 2014$307.90M-21.7%
FY2013Dec 31, 2013$393.36M+85.8%
FY2012Dec 31, 2012$211.72M-1.2%
FY2011Dec 31, 2011$214.22M+11.1%
FY2010Dec 31, 2010$192.89M+4362.0%
FY2009Dec 31, 2009$4.32M–
FY2008Dec 31, 2008-$164.84M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$205.60M+58.8%
Q1 FY2026Mar 31, 2026$362.50M-6.2%
Q4 FY2025Dec 31, 2025$173.30M-31.9%
Q3 FY2025Sep 30, 2025$351.60M+16.9%
Q2 FY2025Jun 30, 2025$129.50M-30.8%
Q1 FY2025Mar 31, 2025$386.30M+14.2%
Q4 FY2024Dec 31, 2024$254.50M+253.5%
Q3 FY2024Sep 30, 2024$300.70M+7.2%
Q2 FY2024Jun 30, 2024$187.10M+203.7%
Q1 FY2024Mar 31, 2024$338.30M+1.4%
Q4 FY2023Dec 31, 2023$72.00M-18.8%
Q3 FY2023Sep 30, 2023$280.50M+47.8%
Q2 FY2023Jun 30, 2023$61.60M-44.0%
Q1 FY2023Mar 31, 2023$333.50M+21.2%
Q4 FY2022Dec 31, 2022$88.70M-14.7%
Q3 FY2022Sep 30, 2022$189.80M+16.9%
Q2 FY2022Jun 30, 2022$110.00M-16.6%
Q1 FY2022Mar 31, 2022$275.20M+247.5%
Q4 FY2021Dec 31, 2021$104.00M-8.7%
Q3 FY2021Sep 30, 2021$162.30M-31.0%
Q2 FY2021Jun 30, 2021$131.90M-9.5%
Q1 FY2021Mar 31, 2021$79.20M-60.7%
Q4 FY2020Dec 31, 2020$113.90M+46.4%
Q3 FY2020Sep 30, 2020$235.10M+36.8%
Q2 FY2020Jun 30, 2020$145.80M+29.5%
Q1 FY2020Mar 31, 2020$201.60M–
Q4 FY2019Dec 31, 2019$77.80M+131.5%
Q3 FY2019Sep 30, 2019$171.80M-12.3%
Q2 FY2019Jun 30, 2019$112.60M-10.8%
Q1 FY2019Mar 31, 2019-$652.50M-374.0%
Q4 FY2018Dec 31, 2018$33.60M–
Q3 FY2018Sep 30, 2018$196.00M-17.1%
Q2 FY2018Jun 30, 2018$126.30M+153.6%
Q1 FY2018Mar 31, 2018$238.10M+10.6%
Q4 FY2017Dec 31, 2017-$113.60M-176.4%
Q3 FY2017Sep 30, 2017$236.50M+7.7%
Q2 FY2017Jun 30, 2017$49.80M–
Q1 FY2017Mar 31, 2017$215.20M–
Q4 FY2016Dec 31, 2016$148.70M–
Q3 FY2016Sep 30, 2016$219.60M–

More United Therapeutics figures

See a number that looks wrong?